Orasi Medical Appoints New CEO and Expands its Board of Directors
News May 18, 2011
Orasi Medical has named Rajiv Khosla as the company's President, Chief Executive Officer and member of the Board of Directors, effective immediately.
Mark Wagner, Chairman of the Board, said, "We are very excited that Rajiv Khosla has joined Orasi Medical as CEO. Rajiv is a seasoned and accomplished technology executive and is the savvy and dynamic leader that the Board was seeking. We're confident that Rajiv's leadership will maximize shareholder value through his proven operational leadership, energetic style, and extensive track record of successful new product launches."
Dr. Khosla is an accomplished business executive with over 25 years of experience in various sectors of the life sciences industry, including pharmaceuticals, medical devices, and specialty chemicals. His career includes senior positions in general management and corporate development.
Most recently, Dr. Khosla was Vice President Business Development at Biovail Pharmaceuticals, Inc., where he successfully led and concluded several specialty CNS transactions in neurology and psychiatry. Prior to this, Dr. Khosla led and managed the pharmaceutical and medical device businesses at ISP Inc., ICI, and Sensient Technologies.
Dr. Khosla has a Ph.D. in pharmaceutical science and a Bachelor of Pharmacy from the University of Nottingham (UK), an MBA from Henley Management College (UK), and is a registered Pharmacist (UK).
"It's a great honor to join the talented team at Orasi Medical and its dynamic Board of Directors. I am excited about establishing the Orasi technology in the rapidly growing field of CNS diagnostics," said Dr Khosla.
Orasi Medical also announces the expansion of its Board, with the addition of Robert F. Butz. Dr. Butz brings to Orasi's Board his expertise in the pharmaceutical and contract research industry. He has held senior positions at Biovail Pharmaceuticals, MDS Pharma Services, Polymerix Corporation, Copernicus Therapeutics, Sensus Drug Development Corporation, and Amylin Pharmaceuticals.
Dr. Butz is on the faculty at the Tufts Center for the Study of Drug Development, and is an elected member of the American Society of Clinical Pharmacology and Therapeutics as well as the American Society of Pharmacology and Experimental Therapeutics.